Riverbridge Partners LLC Has $44.19 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Riverbridge Partners LLC reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 239,388 shares of the medical research company’s stock after selling 27,059 shares during the quarter. Riverbridge Partners LLC’s holdings in Charles River Laboratories International were worth $44,191,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP grew its holdings in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares in the last quarter. Earnest Partners LLC grew its stake in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Charles River Laboratories International by 73.6% during the second quarter. The Manufacturers Life Insurance Company now owns 239,913 shares of the medical research company’s stock worth $49,561,000 after buying an additional 101,732 shares in the last quarter. Finally, Mizuho Securities USA LLC raised its stake in shares of Charles River Laboratories International by 2,336.4% in the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after acquiring an additional 92,895 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Redburn Atlantic started coverage on Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday. UBS Group reiterated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Stock Performance

CRL stock opened at $168.27 on Thursday. Charles River Laboratories International, Inc. has a twelve month low of $160.85 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The company has a market cap of $8.61 billion, a P/E ratio of 21.06, a price-to-earnings-growth ratio of 5.97 and a beta of 1.38. The business’s fifty day moving average is $187.81 and its 200-day moving average is $197.72.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.72 earnings per share. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).